Document:

a1015redlineamendmentnum

                                                             Exhibit 10.15                                                   ***Text Omitted and Filed Separately with                                                   the Securities and Exchange Commission.                                                   Confidential Treatment Requested Under                                                 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.        AMENDMENT NUMBER TWO TO PLATFORM LICENSE AGREEMENT        This Amendment Number Two to Platform License Agreement (this “ Amendment  No. 2”) is entered into effective as of June 25, 2018 (“Amendment No. 2 Effective Date ”) and made by and between OMT, Inc. (“ OMT ”), which has its principal place of business at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121, U.S.A., and Wuxi Biologics Ireland Limited (“ Licensee ”), which has its principal place of business at One Spencer Dock, North Wall Quay, Dublin 1, Ireland.  OMT and Licensee may each be referred to herein as a “ Party ” and collectively as the “ Parties .”        WHEREAS ,  OMT  and  WuXi  AppTec  Biopharmaceuticals  Co.,  Ltd.,  which  has  its principal  place  of  business  at  108  Meiliang  Rd.,  Mashan,  Wuxi,  P.R.  China,  entered  into  the Platform License Agreement, effective on March 23, 2015 (the “ Original Agreement ”);        WHEREAS ,  pursuant  to  the  Assignment  and  Assumption  Agreement  entered  by  and among OMT, WuXi AppTec Biopharmaceuticals Co., Ltd., and Wuxi Biologics (Hong Kong) Limited as of July 19, 2016, WuXi AppTec Biopharmaceuticals Co., Ltd. assigned the Original Agreement to Wuxi Biologics (Hong Kong) Limited;        WHEREAS ,  OMT  and  Wuxi  Biologics  (Hong  Kong)  Limited  amended  the  Original Agreement by Amendment Number One to Platform License Agreement, effective as of June 11, 2017 (together with the Original Agreement, the “ Agreement ”);        WHEREAS ,  pursuant  to  the  Assignment  and  Assumption  Agreement  entered  by  and among  the  Parties  and  Wuxi  Biologics  (Hong  Kong)  Limited  as  of  June  25,  2018,  Wuxi Biologics (Hong Kong) Limited assigned the Agreement to Licensee; and        WHEREAS , the Parties desire to amend certain terms of the Agreement in accordance with this Amendment No. 2.        NOW   T HEREFORE ,  for  good  and  valuable  consideration,  the  receipt and  sufficiency  of which is hereby acknowledged by the Parties, the Parties, intending to be legally bound, agree as follows:  1.    All  capitalized  terms  used  in  this  Amendment  No. 2  and  not  otherwise  defined  in  this       Amendment No. 2 shall have the meanings assigned to such terms in the Agreement.  2.    Within ten (10) days of the Amendment No. 2 Effective Date, Licensee shall pay OMT       fifty-one   million   U.S.   dollars   (US   $51   million),   which   is   in   lieu   of   any   milestone       payments  that  will  become  due  or  payable  arising  under  the  Agreement  after  the       Amendment  No.  2  Effective  Date [***] .  Upon receipt of the payment described in this        [***]  Certain information on this page has been omitted and filed separately with the 4840-7056-1386 v.6                 1   US-DOCS\102805239.1102810859.2 

 

      Paragraph 2, above, OMT acknowledges and agrees that Licensee shall have no further       obligation to pay any milestone payments under the Agreement.  3.    The following shall be added to the end of Section 3.1 of the Agreement:             “If, OMT intends to or does cease supplying Animals directly or through            authorized third parties in accordance with this Section 3.1 for more than            five (5) consecutive months for any reason including, but not limited to,            bankruptcy of OMT, voluntary or involuntary cessation of OMT’s Animal            supply  business,  or  change  of  control  of  OMT,  OMT  shall  immediately            notify  Licensee  in  writing  of  such  intent  or  cessation, and, to the extent            permitted under applicable law, shall grant to Licensee the right to breed            the  Animals  for  use  consistent  with  this  Agreement,  under  any  and  all            intellectual property rights, including but not limited to any and all patents            and patent applications, know-how, and trade secrets, owned or otherwise            controlled by OMT that are necessary for Licensee to breed the Animals            for use consistent with this Agreement, and shall transfer to Licensee the            technologies that are necessary for Licensee to breed the Animals for use            consistent  with  this  Agreement  (“Animal   Technology   Transfer ”).   OMT            shall  provide  reasonable  technical  assistance  requested  by  Licensee  to            enable  the  Animal  Technology  Transfer  and  shall  execute  any            documentation reasonably necessary to transfer such technology and any            regulatory  or  other  governmental  consents  or  approvals  regarding  the            same, and will novate any contracts with any third party that relate solely            to  the  provision  of  such  Animals  to  the  benefit  of Licensee.   For  the            avoidance of doubt, the royalty obligations provided in Sections 5.2(a), (b)            and (c) will remain unchanged.”  4.    Section  4.2(a)  of  the  Agreement  shall  be  deleted in  its  entirety  and  replaced  with  the       following:             “Relative to OMT, Licensee will exclusively own the Antibodies and any            Products  (including  Products  developed  by  any  Outlicensee)  and  all            intellectual property rights therein, including any patent rights, developed            by  Licensee  or  any  such  Outlicensee  at  any  time  under  this  Agreement            (collectively,  “IP   Rights ”),  and  each  hereby  makes  all  assignments            necessary to achieve the foregoing.  Subject to compliance with all terms            and  conditions  of  this  Agreement,  Licensee  hereby  grants  OMT  a  non-            exclusive,  irrevocable,  perpetual,  worldwide,  royalty-free,  non-            sublicenseable, non-transferable right and license in and to the IP Rights,            to  the  extent  necessary  to  allow  OMT  to  exercise  its  rights  hereunder         Commission.  Confidential treatment has been requested with respect to the       omitted portions.  4840-7056-1386 v.6                                    2 US-DOCS\102805239.1102810859.2 

 

           and/or  to  allow  OMT  to  exploit  such  IP  Rights  for  non-commercial            purposes including research, provided that  OMT will not distribute, sell,            offer  for  sale,  use,  or  otherwise  transfer  any  such  Antibodies  and            Products.”  5.    Section  4.2(b)  of  the  Agreement  shall  be  deleted in  its  entirety  and  replaced  with  the       following:             “No  less  frequently  than  once  per  each  calendar  quarter,  Licensee  shall            provide  to  OMT  a  report  summarizing  Licensee’s  and Outlicensees’            prosecution  and  maintenance  activities  regarding  any  patent  rights  with            respect  to  the  IP  Rights,  including,  if  requested  by  OMT,  copies  of  any            significant office actions, communications, and correspondence relating to            such  patent  rights.   OMT  shall  have  the  right  to  comment  on  and  to            discuss  such  activities,  and  Licensee  shall  consider  (and  cause  the            applicable Outlicensees to consider) OMT’s comments in good faith.”  6.    Section  4.3(a)  of  the  Agreement  shall  be  deleted in  its  entirety  and  replaced  with  the       following:             “China   Outlicensing   Agreement .   Licensee  may  authorize,  including            without limitation under an assignment, a license or option grant and/or an            appointment  as  distributor,  a  third  party  to  use,  develop,  market,            distribute,  offer  for  sale,  and/or  sell  an  Antibody  in  China  (and,  as            applicable with respect to Existing Antibodies, the China Plus Territory)            solely  pursuant  to  an  agreement  that  is  consistent with  the  terms  and            conditions  of  this  Agreement,  including  without  limitation  this  Section            4.3(a)  (each  such  third  party  agreement,  a  “China   Outlicensing            Agreement ”).  Pursuant to a China Outlicensing Agreement, Licensee may            distribute or otherwise transfer any Antibodies generated by or on behalf            of Licensee to the applicable China Outlicensee using antigens selected by            Licensee  or  such  China  Outlicensee.   Licensee  shall  be  responsible  and            liable  for  all  actions  and  omissions  of  China  Outlicensees  in  connection            with  any  such  Antibodies.   Licensee  may  provide  (i)  any  such  resulting            Antibodies to a China Outlicensee that is bound by a China Outlicensing            Agreement;  and  (ii)  Existing  Antibodies  to  a  China Outlicensee  that  is            bound by a written addendum to such China Outlicensing Agreement for            use,  development,  and  marketing  in  the  China  Plus  Territory  (a  “China            Plus   Addendum ”,  which  shall  be  deemed  a  part  of  the  applicable  China            Outlicensing  Agreement).   Each  China  Outlicensing  Agreement  will            include  payment  provisions  that  enable  Licensee  to comply  with  its            obligations  to  make  payments  to  OMT  under  this  Agreement,  and  will            prohibit  the  licensing,  distribution,  sale,  offer  for  sale,  use,  or  other            transfer  of  any  Antibody  or  Product outside of China (and as applicable            with  respect  to  Existing  Antibodies,  the  China  Plus  Territory)  by  or  on   4840-7056-1386 v.6                                    3 US-DOCS\102805239.1102810859.2 

 

           behalf  of  the  applicable  China  Outlicensee,  where  “use”  includes            development of and distribution of Products.”  7.    The last sentence of Section 4.3(b) of the Agreement shall be deleted in its entirety and       replaced with the following sentence:             “Each  Ex-China  Outlicensing  Agreement  will  prohibit  the  licensing,            distribution, sale, offer for sale, use, or other transfer of any Antibody or            Product in and/or into China (and, as applicable, with respect to Existing            Antibodies, the China Plus Territory) by or on behalf of the applicable Ex-            China Outlicensee, where “use” includes development of and distribution            of Products.”  8.    Section  4.3(d)  of  the  Agreement  shall  be  deleted in  its  entirety  and  replaced  with  the       following:             “Licensee may not outlicense or otherwise provide rights in any Antibodies            to any third party except pursuant to Section 4.3(a), (b), and/or (c).”  9.    The first sentence of Section 4.3(f) of the Agreement shall be deleted and replaced with the following sentence:             “Each  Outlicensing  Agreement  shall  contain  terms  no  less  protective  of            OMT  (including  without limitation OMT’s intellectual property rights in            the  Animals  and  Animal  Improvements)  than  those  set  forth  in  this            Agreement.”  10.   The last sentence of Section 4.3(f) of the Agreement shall be deleted and replaced with the following sentence:             “Licensee  will  keep  OMT  reasonably  informed  of  the  status  of  any            Outlicensing Agreements, and promptly after execution of the Outlicensing            Agreement,  Licensee  shall  provide  to  OMT  a  full  copy  of  such            Outlicensing  Agreement  (with  any  confidential  or  financial  terms            redacted), translated into English if applicable. ”  11.   Section  4.4  of  the  Agreement  shall  be  deleted  in  its  entirety  and  replaced  with  the following:             “As  between  the  parties,  and  without  limiting  any  other  available  remedy,            OMT   owns   (i)   the   Animals   and   (ii)   any   modification,   improvement,            enhancement,   or   progeny   of   the   Animals   ( “Animal   Improvements ”)            created  in  violation  of  Section  4.1(a)  above,  and  all  intellectual  property            rights  in  any  of  the  foregoing.   Licensee  hereby  makes  (and  will  cause  its            Approved   Affiliates   and   its   and   their   Approved  Subcontractors,  and  any            Outlicensee,   as   applicable,   to   make)   all   assignments   necessary   to  4840-7056-1386 v.6                                    4 US-DOCS\102805239.1102810859.2 

 

           accomplish   the   foregoing   ownership   with   respect   to   any   Animal            Improvements.   Licensee   acknowledges   and   agrees   that   the   Animals   and            Animal   Improvements,   together   with   any   related   biological   material   or            substance   that   is   replicated,   synthesized   or   in   any   way   derived   from   the            Animals (including progeny), except for Antibodies, include and constitute            valuable   trade   secrets   of   OMT,   and   OMT   has   used   diligent   efforts   to            maintain such items as its trade secrets and Confidential Information .”  12.   Section  4.5(a)  of  the  Agreement  shall  be  deleted  in  its  entirety  and  replaced  with  the following:             “Each  of  OMT  and  Licensee  shall  notify  the  other  promptly  in  writing            when each learns of or reasonably suspects infringement of any IP Rights            by a third party (an “Infringement ”).  Licensee, and its Outlicensees, shall            have the first right to enforce any IP Right in the Territory, and control,            defend,  and  settle  such  suit  in  a  manner  consistent  with  the  terms  and            provisions  of  this  Agreement,  and  recover  any  damages,  awards,  or            settlements resulting therefrom, subject to Section 4.5(c).  OMT agrees to            use commercially reasonable efforts to reasonably cooperate in any such            litigation, including participating in a suit if required to provide standing.”  13.   Section  4.5(b)  of  the  Agreement  shall  be  deleted  in  its  entirety  and  replaced  with  the following:             “If Licensee or its Outlicensee does not bring suit to enforce the applicable            IP Rights with respect to an Infringement within one hundred and eighty            (180)  days  of  becoming  aware  that  such  Infringement exists, then OMT            may, in its sole judgment and at its own expense, take steps to enforce any            such rights, including instituting suit against any such infringer or alleged            infringer, and control, defend and settle such suit in a manner consistent            with the terms and provisions hereof, and recover any damages, awards or            settlements resulting therefrom, subject to Section 4.5(c).  Licensee agrees            to reasonably cooperate in any such litigation, including participating in a            suit if required to provide standing.”  14.   A new Section 4.8 shall be added to the Agreement as follows:             “Non-Animal  Improvements .  Licensee, or Outlicensees, shall solely own            any improvements developed by Licensee or any such Outlicensee to the            Antibodies and Products that are not Animal Improvements (“Non-Animal            Improvements ”).   Non-Animal  Improvements  are  derivatives  of            Antibodies, bispecific/multispecific antibodies, Antibody-drug conjugates,            and any drugs or further products generated from the Antibodies, in each            case to the extent that it is not an Animal Improvement.  All intellectual            property  rights  developed  by  Licensee  or  an  Outlicensee  in  any  Non-            Animal Improvement at any time under this Agreement shall be exclusively  4840-7056-1386 v.6                                    5 US-DOCS\102805239.1102810859.2 

 

           owned by Licensee or the Outlicensee.  For the avoidance of doubt, Non-            Animal Improvements do not include Animals or Animal Improvements.”  15.   A new Section 5.1(d) shall be added to the Agreement as follows:             “Licensee   shall   be   required   to   make   each   of   the   payments   set   forth   in            Sections   5.1(a),   (b),   and   (c)   only   if   such   payment   becomes   payable   in            accordance  with  the  terms  of  Section  5.1(a),  (b),  or  (c)  on  or  before  the            Amendment  No.  2  Effective  Date .   For   clarity,   Licensee   shall   not   be            required  to  make  any  payment  set  forth  in  Sections  5.1(a),  (b),  and  (c)  if            such   payment   becomes   payable   in   accordance   with   the  terms  of  Section            5.1(a), (b), or (c) after  the Amendment No. 2 Effective Date. ”  16.   All  instances  of  the  term  “Joint  Rights”  in the Agreement that are not modified by the       above provisions are hereby modified to the term “IP Rights”. The Parties agree that this       Paragraph 16 retroactively applies to all Outlicensee Agreements entered into even before       this Amendment No. 2 Effective Date.  17.   In  the  event  that  OMT  does  not  receive  the fifty-one   million   U.S.   dollars   (US   $51       million)  [***]  set forth in Paragraph 2 of this Amendment No. 2 within ten (10) days of       the  Amendment  No.  2  Effective  Date,  OMT  will  have  the  right  to  terminate  this       Amendment No. 2 immediately upon written notice.  If OMT terminates this Amendment       No. 2 as set forth in this Paragraph 17, above, this Amendment No 2 shall have no force       or  effect,  retroactive to the Amendment No 2 Effective Date, and the Agreement shall       continue  in  full  force  and  effect  as  it  existed  prior  to  the  Amendment  No.  2  Effective       Date.  18.   In the event of any discrepancies or conflicting terms between this Amendment No. 2 and       the Agreement, the terms of this Amendment No. 2 shall control.  19.   The  Agreement  and  this  Amendment  No.  2  represent  the  complete  and  entire       understanding between the Parties regarding the subject matter hereof and supersede all       prior or contemporaneous negotiations, representations or agreements, either written or       oral, regarding this subject matter.  20.   This Amendment No. 2 and the rights and obligations of the Parties hereunder shall be       governed  by  the  laws  of  the  State  of  California, without regard to the conflicts of law       provisions thereof.         [***]  Certain information on this page has been omitted and filed separately with the       Commission.  Confidential treatment has been requested with respect to the       omitted portions.  4840-7056-1386 v.6                                    6 US-DOCS\102805239.1102810859.2 

 

21.   This Amendment No. 2 may be executed in counterparts, each of which shall be deemed       an original and, together, one and the same instrument.  A facsimile, PDF or any other       copy of this Amendment No. 2 signed by a Party is binding upon the signing Party to the       same  extent  as  the  original  of  the  signed  Amendment  No.  2,  and  may  be  delivered       electronically.  22.   Except  for  the  matters  set  forth  in  this  Amendment  No.  2,  all  other  terms  of  the       Agreement shall remain unchanged and in full force and effect.                             [Signature page follows.]   4840-7056-1386 v.6                                    7 US-DOCS\102805239.1102810859.2 

 

IN W ITNESS  W HEREOF , the Parties hereto have duly executed this Amendment No. 2:  OMT, INC.                                 WUXI BIOLOGICS IRELAND                                           LIMITED By:    /s/ Charles Berkman                By:    /s/ Chris Chen Name:  Charles Berkman                    Name:  Chris Chen Title: VP & Secretary                     Title: Director Date:  June 25, 2018                      Date:  June 24, 2018   4840-7056-1386 v.6                                       8 US-DOCS\102805239.1102810859.2 

 

                       Summary report:    Litéra® Change-Pro TDC 10.1.0.400 Document comparison done on                      8/7/2018 11:54:53 AM Style name: L&W with Moves Intelligent Table Comparison: Active Original DMS: iw://US-DOCS/US-DOCS/102810859/1 Modified DMS: iw://US-DOCS/US-DOCS/102810859/2 Changes: Add                                            12 Delete                                         6 Move From                                      0 Move To                                        0 Table Insert                                   0 Table Delete                                   0 Table moves to                                 0 Table moves from                               0 Embedded Graphics (Visio, ChemDraw, Images etc.) 0 Embedded Excel                                 0 Format changes                                 0 Total Changes:                                 18Exhibit

Exhibit 10.1

Personal Usage of Aircraft Policy (“Policy”)

	
			
	Owner
	Published
	Version

	Legal
	April 1, 2018
	1.0

Liberty Latin America Ltd. (the “Company”), desires to provide the members of the Company’s Board of Directors (each, a “Director”), the Chief Executive Officer (“CEO”), certain senior executives of the Company and its subsidiaries (each, an “Executive”), and other individuals as may be approved by the CEO or the Company’s Chief Legal Officer (each, an “Affiliate”) the benefit of personal usage of aircraft owned in whole or in part by the Company or a subsidiary thereof (“Company Aircraft”) when the same is not being used for a business purpose, subject to the terms and conditions set forth in this Policy.  Each Director, Executive, Affiliate, and the CEO is sometimes hereinafter referred to as a “Personal User.”

This Policy is intended to comply with all applicable rules and regulations of the Federal Aviation Administration (“FAA”) and Internal Revenue Service (“IRS”) and shall be amended from time to time as necessary or appropriate to ensure continued compliance with all such rules and regulations as in effect at such time.  This Policy shall further be subject to amendment, modification or termination in the sole discretion of the Company’s Board of Directors.

APPROVAL

Any use of the Company Aircraft by a Personal User other than the CEO for a personal trip or to bring a family member or guest on a business trip must be approved in advance by the CEO or the Company’s Chief Legal Officer. 

Any use of the Company Aircraft by the CEO for personal trips in any calendar year that, when taken together with his use for personal trips of any aircraft to which the Company has rights of use under a time sharing or other agreement or arrangement, aggregate more than 20 flight hours in excess of his Compensatory Hours for that year must be approved by the Chairman of the Board of Directors.  For purposes of this Policy, “Compensatory Hours” means the number of flight hours of personal use in any calendar year that has been approved as part of the CEO’s compensation package by the Compensation Committee of the Company’s Board of Directors.  

PERSONAL TRIPS

Subject to the following paragraph, a Personal User will pay to the Company for each usage of the Company Aircraft for a personal trip an amount equal to the aggregate incremental cost to the Company and its subsidiaries of such usage, determined in a manner consistent with the applicable rules and regulations (and interpretations thereof) of the Securities and Exchange Commission related to disclosure of executive compensation (the “SEC Calculation”).  The amount charged the Personal User in accordance with the SEC Calculation will be subject to federal excise tax of 7.5% and may not exceed any limits set forth in the FAA regulations.

The foregoing payment obligations will not apply to the CEO’s usage of the Company Aircraft for personal trips until after his Compensatory Hours for the relevant calendar year have been exhausted.  Further, the foregoing payment obligations do not apply to non-employee Directors.

	
			
	Liberty Latin America Ltd. reserves the right to amend or cancel this Policy at any time.

	

.

TAX RAMIFICATIONS

For income tax purposes, the value of a flight on the Company Aircraft taken by a Personal User not traveling on business, non-business related guests, or family members is generally taxable as a fringe benefit to the Personal User.  For U.S. federal income tax purposes, the IRS requires such value to be determined by the Standard Industry Fare Level (“SIFL”) method of calculation (the “SIFL Calculation”).  For a Personal User not subject to U.S. federal income tax (either generally or with respect to the specific flight), such value will be determined in accordance with the applicable laws and regulations in the relevant tax jurisdiction (the “Non-US Tax Calculation”).  For business trips with non-business passengers, the Personal User will be imputed income for those non-business passengers attributable to him or her, unless an exception applies under applicable law.  The amount imputed as income will be calculated pursuant to the SIFL Calculation or the Non-US Tax Calculation, as applicable.

To the extent a Personal User has paid the Company for aircraft usage under the SEC Calculation, that amount will be offset against the applicable SIFL Calculation or the Non-US Tax Calculation.  If the amount paid is less than the applicable SIFL Calculation or the Non-US Tax Calculation, only the difference will be imputed as income to the Personal User.

TIME SHARING AGREEMENTS 

To use the Company Aircraft as provided above, the Personal User must lease it.  Such lease will be through an Aircraft Time Sharing Agreement executed by the Personal User in the form approved by the Company, prior to any personal usage of the Company Aircraft.

SCHEDULE DECISIONS

Notwithstanding the foregoing policy or the terms of the Aircraft Timing Sharing Agreements, the Company and its flight crew retain the authority to determine when a flight may be cancelled or changed for safety or maintenance reasons.  Also, the Company retains authority to determine what flights may be scheduled based on the business needs of the Company.  Although the Company will use its best efforts to accommodate personal use requests, business needs will take priority in any scheduling conflicts.

	
			
	Liberty Latin America Ltd. reserves the right to amend or cancel this Policy at any time.

	

.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]